Sendayco LLC Acquires Reviva Labs

Crown Laboratories Acquires Revance Therapeutics

August 12, 2024

Biotechnology

Crown Laboratories, a Hildred Capital portfolio company, completed the acquisition of Revance Therapeutics through a cash tender offer that expired February 4, 2025; the transaction closed on February 6, 2025 and Revance will be delisted from Nasdaq. The deal brings together Crown's skincare and consumer brands with Revance's DAXXIFY, RHA dermal fillers and other aesthetics/therapeutic offerings to expand product portfolio and commercialization capabilities across medical, retail and e-commerce channels.

Studio Science Acquires RevTech360

March 22, 2023

IT Services

Studio Science, a design and innovation consultancy backed by Inoca Capital Partners, has acquired RevTech360, a MuleSoft- and Salesforce-focused digital transformation and CRM consulting firm based in Indianapolis. The acquisition bolsters Studio Science’s Salesforce Commerce Cloud and cross-cloud integration capabilities and adds certified architects and developers to its enterprise offerings.

Grove Collaborative Acquires Sundaily

June 18, 2020

Consumer Products

Grove Collaborative has acquired Sundaily, an ingestible skincare gummy brand, to expand its wellness and beauty product portfolio. Sundaily's co-founders will join Grove in advisory roles and operations will move to Grove's San Francisco headquarters.

Validant Acquires DataRevive

November 1, 2019

Healthcare Services

Validant, a transatlantic quality, compliance and regulatory consulting group backed by GHO Capital, has acquired DataRevive, a regulatory strategy and consulting firm focused on novel therapeutics and biologics. The deal expands Validant's capabilities in life‑science regulatory consulting and adds a Washington, D.C. location to its existing footprint in San Francisco, Research Triangle Park and Cork, Ireland.

Aurora Cannabis Acquires Reliva LLC

May 28, 2020

Consumer Products

Aurora Cannabis Inc. completed the acquisition of Reliva, LLC, a leading U.S. hemp-derived CBD consumer brand, in a transaction valued at approximately US$40 million in Aurora common shares plus an earn-out of up to US$45 million. The deal gives Aurora immediate U.S. retail CBD scale and distribution (Reliva products are sold in over 20,000 stores) and aims to combine Aurora's product innovation and international footprint with Reliva's U.S. retail relationships to accelerate growth.

Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

February 11, 2020

Pharmaceuticals

Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.